Authors:
Piketty, C
Jayle, D
Leplege, A
Castiel, P
Ecosse, E
Gonzalez-Canali, G
Sabatier, B
Boulle, N
Debuire, B
Le Bouc, Y
Baulieu, EE
Kazatchkine, MD
Citation: C. Piketty et al., Double-blind placebo-controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease, CLIN ENDOCR, 55(3), 2001, pp. 325-330
Authors:
Landau, A
Batisse, D
Piketty, C
Van Huyen, LPD
Bloch, F
Belec, L
Bruneval, P
Weiss, L
Jian, R
Kazatchkine, MD
Citation: A. Landau et al., Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients, AIDS, 15(16), 2001, pp. 2149-2155
Authors:
Piketty, C
Weiss, L
Thomas, F
Mohamed, AS
Belec, L
Kazatchkine, MD
Citation: C. Piketty et al., Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen, J INFEC DIS, 183(9), 2001, pp. 1328-1335
Authors:
Piketty, C
Bardin, C
Gilquin, J
Gairard, A
Kazatchkine, MD
Chast, F
Citation: C. Piketty et al., Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis, CL MICRO IN, 6(3), 2000, pp. 117-120
Authors:
Landau, A
Batisse, D
Van Huyen, JPD
Piketty, C
Bloch, F
Pialoux, G
Belec, L
Petite, JP
Weiss, L
Kazatchkine, M
Citation: A. Landau et al., Efficacy and safety of combination therapy with interferon-alpha 2b and ribavirin for chronic hepatitis C in HIV-infected patients, AIDS, 14(7), 2000, pp. 839-844
Authors:
Piketty, C
Race, E
Castiel, P
Belec, L
Peytavin, G
Si-Mohamed, A
Gonzalez-Canali, G
Weiss, L
Clavel, F
Kazatchkine, MD
Citation: C. Piketty et al., Phenotypic resistance to protease inhibitors in patients who fail on highly active antitetroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz, AIDS, 14(5), 2000, pp. 626-628
Authors:
Landau, A
Batisse, D
Piketty, C
Jian, R
Kazatchkine, MD
Citation: A. Landau et al., Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy, AIDS, 14(12), 2000, pp. 1857-1858
Authors:
Karmochkine, M
Mohamed, AS
Piketty, C
Ginsburg, C
Raguin, G
Schneider-Fauveau, V
Gutmann, L
Kazatchkine, MD
Belec, L
Citation: M. Karmochkine et al., The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients, ANTIVIR RES, 47(3), 2000, pp. 179-188
Authors:
Belec, L
Piketty, C
Si-Mohamed, A
Goujon, C
Hallouin, MC
Cotigny, S
Weiss, L
Kazatchkine, MD
Citation: L. Belec et al., High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure ofprotease inhibitor-containing antiretroviral combination therapy, J INFEC DIS, 181(5), 2000, pp. 1808-1812
Authors:
Piketty, C
Castiel, P
Giral, P
Lhomme, JP
Boubilley, D
Olievenstein, C
Lert, F
Kazatchkine, MD
Citation: C. Piketty et al., Lack of legal income is strongly associated with an increased risk of AIDSand death in HIV-infected injecting drug users, AIDS CARE, 11(4), 1999, pp. 429-436
Authors:
Piketty, C
Race, E
Castiel, P
Belec, L
Peytavin, G
Si-Mohamed, A
Gonzalez-Canali, G
Weiss, L
Clavel, F
Kazatchkine, MD
Citation: C. Piketty et al., Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy, AIDS, 13(11), 1999, pp. F71-F77